Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2012, 5(10), 1128-1146; doi:10.3390/ph5101128
Review

Advances in Drug Design Based on the Amino Acid Approach: Taurine Analogues for the Treatment of CNS Diseases

* ,
,
,
,
 and
Received: 31 July 2012; in revised form: 24 September 2012 / Accepted: 15 October 2012 / Published: 23 October 2012
(This article belongs to the Special Issue Advances in Drug Design)
View Full-Text   |   Download PDF [337 KB, updated 24 October 2012; original version uploaded 23 October 2012]
Abstract: Amino acids are well known to be an important class of compounds for the maintenance of body homeostasis and their deficit, even for the polar neuroactive aminoacids, can be controlled by supplementation. However, for the amino acid taurine (2-aminoethanesulfonic acid) this is not true. Due its special physicochemical properties, taurine is unable to cross the blood-brain barrier. In addition of injured taurine transport systems under pathological conditions, CNS supplementation of taurine is almost null. Taurine is a potent antioxidant and anti-inflammatory semi-essential amino acid extensively involved in neurological activities, acting as neurotrophic factor, binding to GABA A/glycine receptors and blocking the excitotoxicity glutamate-induced pathway leading to be a neuroprotective effect and neuromodulation. Taurine deficits have been implicated in several CNS diseases, such as Alzheimer’s, Parkinson’s, epilepsy and in the damage of retinal neurons. This review describes the CNS physiological functions of taurine and the development of new derivatives based on its structure useful in CNS disease treatment.
Keywords: amino acid; CNS; taurine; analogs amino acid; CNS; taurine; analogs
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Chung, M.C.; Malatesta, P.; Bosquesi, P.L.; Yamasaki, P.R.; Santos, J.L.; Vizioli, E.O. Advances in Drug Design Based on the Amino Acid Approach: Taurine Analogues for the Treatment of CNS Diseases. Pharmaceuticals 2012, 5, 1128-1146.

AMA Style

Chung MC, Malatesta P, Bosquesi PL, Yamasaki PR, Santos JL, Vizioli EO. Advances in Drug Design Based on the Amino Acid Approach: Taurine Analogues for the Treatment of CNS Diseases. Pharmaceuticals. 2012; 5(10):1128-1146.

Chicago/Turabian Style

Chung, Man C.; Malatesta, Pedro; Bosquesi, Priscila L.; Yamasaki, Paulo R.; Santos, Jean Leandro dos; Vizioli, Ednir O. 2012. "Advances in Drug Design Based on the Amino Acid Approach: Taurine Analogues for the Treatment of CNS Diseases." Pharmaceuticals 5, no. 10: 1128-1146.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert